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Background: Several studies show the importance of accurately quantifying not only KRAS and other low-abundant mutations
because benefits of anti-EGFR therapies may depend on certain sensitivity thresholds. We assessed whether ultra-selection of
patients using a high-sensitive digital PCR (dPCR) to determine KRAS, NRAS, BRAF and PIK3CA status can improve clinical
outcomes of panitumumab plus FOLFIRI.
Patients and methods: This was a single-arm phase II trial that analysed 38 KRAS, NRAS, BRAF and PIK3CA hotspots in tumour
tissues of irinotecan-resistant metastatic colorectal cancer patients who received panitumumab plus FOLFIRI until disease
progression or early withdrawal. Mutation profiles were identified by nanofluidic dPCR and correlated with clinical outcomes
(ORR, overall response rate; PFS, progression-free survival; OS, overall survival) using cut-offs from 0% to 5%. A quantitative PCR
(qPCR) analysis was also performed.
Results: Seventy-two evaluable patients were enrolled. RAS (KRAS/NRAS) mutations were detected in 23 (32%) patients and
RAS/BRAF mutations in 25 (35%) by dPCR, while they were detected in 7 (10%) and 11 (15%) patients, respectively, by qPCR.
PIK3CA mutations were not considered in the analyses as they were only detected in 2 (3%) patients by dPCR and in 1 (1%)
patient by qPCR. The use of different dPCR cut-offs for RAS (KRAS/NRAS) and RAS/BRAF analyses translated into differential clinical
outcomes. The highest ORR, PFS and OS in wild-type patients with their lowest values in patients with mutations were achieved
with a 5% cut-off. We observed similar outcomes in RAS/BRAF wild-type and mutant patients defined by qPCR.
Conclusions: High-sensitive dPCR accurately identified patients with KRAS, NRAS, BRAF and PIK3CA mutations. The
optimal RAS/BRAF mutational cut-off for outcome prediction is 5%, which explains that the predictive performance of qPCR
was not improved by dPCR. The biological and clinical implications of low-frequent mutated alleles warrant further
investigations.
VC The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
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Introduction
Panitumumab is a fully human monoclonal antibody that binds
to epidermal growth factor receptor (EGFR), inhibiting EGFR
pathway and tumour growth. 5-fluorouracil-based chemother-
apy and panitumumab improved survival outcomes in metastat-
ic colorectal cancer (mCRC) [1, 2], although the absolute
benefits are limited and disease course depends on RAS muta-
tions [3].
Mutated KRAS exon 2 was initially claimed responsible for
panitumumab resistance [4], but subsequent analyses revealed
the detrimental effect of other KRAS (exons 3/4) and NRAS
(exons 2/3/4) mutations [5]. Treatment indication was then
restricted to patients without mutant RAS (KRAS/NRAS) exons
2/3/4 in 2013. However, not all wild-type RAS tumours respond
to panitumumab and additional predictive markers should be
identified. Despite the need for further evidence, patients with
mutated BRAF exon 15 appear less likely to benefit from EGFR
antibodies [6, 7] and those with PIK3CA exon 20 mutations may
exhibit worse outcomes [8]. Indeed, tumours with RAS, BRAF or
PIK3CA mutations display a shared gene expression pattern that
can explain resistance to anti-EGFR drugs [9]. Extended muta-
tional analyses may therefore contribute to optimizing the identi-
fication of patients that are more likely to respond to anti-EGFR
therapies.
Mutational testing remains challenging as no clearly standar-
dized procedures have been established and an increasing num-
ber of techniques have been recently developed, including
hypersensitive techniques that may ultra-select patients more ac-
curately [10]. Digital PCR (dPCR) is an increasingly applied tech-
nique based on a sample split into hundreds of smaller reactions
followed by target PCR amplifications. Nanofluidic dPCR
improved the sensitivity of detecting KRAS-mutant alleles in clin-
ical samples, reaching 0.05%–0.1%, and allows a better tumour
classification with a commercially available platform [11].
Subsequent extended RAS and BRAF hotspot analyses suggested
a threshold of 1% of mutated alleles to predict anti-EGFR therapy
response, though the optimal cut-off for the clinical setting
remains to be defined [12, 13].
In light of the above, we prospectively assessed whether ultra-
selection of mCRC patients using high-sensitive nanofluidic
dPCR genotyping of KRAS, NRAS, BRAF and PIK3CA can im-
prove the selection of patients and so optimize clinical outcomes
of panitumumab plus FOLFIRI treatment.
Patients and methods
Study design and participants
This was an open-label, single-arm, phase II trial conducted in the
Departments of Medical Oncology at 12 Spanish hospitals according to
the Declaration of Helsinki and national regulations. It was approved by
the ethics committee and all patients gave their written informed consent
before enrolment.
The study included patients aged 18 years with histologically con-
firmed colorectal adenocarcinoma, wild-type KRAS exon 2 as per the
local or central laboratory conventional technique (wild-type KRAS and
NRAS exons 2/3/4 after the approval of a protocol amendment on 25
July 2013), with 1 initially measurable and unresectable metastatic le-
sion, Karnofsky performance status 70% and adequate bone marrow,
renal, hepatic and metabolic functions. Patients must have received
irinotecan-based chemotherapy for mCRC for 6 weeks and have
exhibited disease progression during this treatment or within the
6 months after its end. DNA extracted from tumour blocks must also be
suitable for high-sensitive analysis. Previous treatment with anti-EGFR
antibodies or small-molecule EGFR tyrosine kinase inhibitors was not
allowed.
Patients received panitumumab 6 mg/kg over a 60-min intravenous
infusion on day 1 in 2-week cycles. FOLFIRI was intravenously adminis-
tered on day 1 in 2-week cycles according to the following schema: irino-
tecan 180 mg/m2 over 30–90-min infusion, leucovorin 400 mg/m2 over
120-min infusion, 5-fluorouracil 400 mg/m2 bolus, 5-fluorouracil
2400 mg/m2 over 46-h infusion. Doses of panitumumab, irinotecan and
5-fluorouracil could be reduced/delayed in case of adverse events (AEs)
as per protocol. Treatment continued until disease progression or un-
acceptable toxicity. Patients were subsequently followed every 3 months
to document progression and survival. The study ended 1 year after the
last patient enrolment.
Tumour assessments were conducted every 10 6 2 weeks until disease
progression according to the Response Evaluation Criteria in Solid
Tumors version 1.1. Overall response rate (ORR) was defined as the pro-
portion of patients with a partial or complete response. Progression-free
survival (PFS) was measured from study inclusion to progression or
death, and overall survival (OS) from enrolment to death. Toxicity was
assessed at every study visit according to the Common Toxicity Criteria
for Adverse Events version 4.0.
Mutational analysis
Mutational analysis was conducted at the Institut Català d’Oncologı́a
(L’Hospitalet de Llobregat, Spain). DNA was extracted from formalin-
fixed paraffin-embedded tumour tissues (primary tumour or metastasis)
and a 38-hotspot panel of KRAS (exons 2/3/4), NRAS (exons 2/3/4),
BRAF (exon 15) and PIK3CA (exon 20) mutations was assessed using a
conventional quantitative PCR (qPCR) machine (LightCycler
VR
480;
Roche Applied Science) and a nanofluidic dPCR platform (Digital
ArrayTM and BioMarkTM Real-Time PCR System; Fluidigm Europe) as
described previously [11, 12]. Mutations assessed in this study are
described in supplementary Table S1, available at Annals of Oncology on-
line. Investigators remained blind to mutational status until the end of
study treatment.
Statistical analysis
The primary end point was ORR, which was calculated according to RAS
(KRAS/NRAS), RAS/BRAF and RAS/BRAF/PIK3CA status (as per proto-
col amendment) assessed by dPCR. ORRs were correlated with dPCR
cut-offs from 0% to 5%, estimating odds ratios, 95% confidence intervals
(CIs) and P-values. The sample size was calculated assuming 55% of
RAS/BRAF/PIK3CA (‘ultra’) wild-type patients, with an expected ORR of
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30% versus 5% in those with mutations. Considering a type I error of
15%, type II error of 20%, loss rate of 10%, the estimated sample size was
82 patients. It was required 45 KRAS/NRAS and BRAF wild-type patients.
Secondary end points included PFS and OS, which were correlated
with the previously described mutational status based on dPCR cut-offs
from 0% to 5%. They were calculated using the Kaplan–Meier method
and log-rank test, estimating hazard ratios, 95% CIs and P-values.
Missing data were not considered in the analyses. All statistical analy-
ses were performed using the Statistical Package for the Social Sciences
version 18.0, with a significance level of 0.05.
Results
Patient characteristics and treatment exposure
Ninety-six patients were consecutively recruited from November
2012 to July 2015, 24 of whom were screening failures (supple-
mentary Figure S1, available at Annals of Oncology online). Thus,
72 patients were finally included in the study; their baseline char-
acteristics are described in Table 1. The median 5-flourouracil-
free interval was 1.7 months (range 0.9–6.4), the median
irinotecan-free interval was 1.6 months (range 0.9–5.6) and the
median oxaliplatin-free interval was 3 months (range 0.9–37.4).
Patients received a median of 11 (1–42) cycles of panitumu-
mab, 10 (1–42) of irinotecan, 9 (1–35) of 5-fluorouracil bolus
and 10 (1–42) of 5-fluorouracil infusion. Their median relative
dose intensities were 81% (38%–104%), 78% (25%–103%), 70%
(0%–102%) and 74% (13%–102%), respectively. Grade 3/4 tox-
icities were reported in 48 (67%) patients (supplementary Table
S2, available at Annals of Oncology online) and treatment discon-
tinuations were mainly due to disease progression (n¼ 47, 65%)
or AEs (n¼ 8, 11%).
Mutational profiles
Primary tumour and liver metastasis samples were available for
mutational analysis in 63 and 9 patients, respectively. Specific
mutations in the population of patients included in the study are
shown in supplementary Table S3, available at Annals of Oncology
online. Mutations in RAS, BRAF or PIK3CA were detected in 12
(17%) patients by conventional qPCR and in 26 (36%) by nano-
fluidic dPCR (detection limited by the technique sensitivity).
qPCR found RAS mutations in 7 (10%) patients (KRAS: n¼ 5;
NRAS: n¼ 2), while dPCR detected them in 23 (32%) (KRAS:
n¼ 20; NRAS: n¼ 5) (Table 2). RAS or BRAF mutations were
detected in 11 (15%) patients using qPCR and in 25 (35%) using
dPCR. Two of the four patients with BRAF mutant tumours by
qPCR showed additional KRAS mutations at low allele fraction.
As only one PIK3CA mutation (H1047R) was detected in 1 (1%)
patient by qPCR and in 2 (3%) by dPCR, it was not considered in
the efficacy outcome analyses.
Efficacy outcomes according to mutational profiles
In the RAS wild-type population by qPCR (N¼ 65), radiologic
tumour response was evaluable in 64 of 65 patients. An inverse
correlation between the proportion of mutant allele and tumour
response is shown in supplementary Figure S2, available at
Annals of Oncology online, although it did not reach statistical
significance (P-value ¼ 0.058). The median percentage of
mutated DNA was 0.8% for responders (0.1%–6.1%) and 9.6%
for non-responders (0.4%–48%). RAS mutations were detected
in 7 of 31 responders (23%) by qualitative dPCR genotyping. In 4
of these 7 responders (57%), the major mutant allele fraction was
below 1% and in 6 of these 7 responders (86%), the major mutant
allele fraction was below 5% (Figure 1). When analysed by qPCR,
ORRs were 48% in patients with wild-type RAS and 51% in those
with wild-type RAS/BRAF and no patient with mutations showed
a response. The bottom line is that when analytical sensitivity is
increased beyond 5%, response rate significantly increases in new
‘ultra’ mutant but not in the new ‘ultra’ wild-type groups, re-
spectively, which remarkably worsens the prediction ability of the
mutational status (Table 3).
As mentioned previously, four of the RAS wild-type tumours
harboured BRAF mutations, detected either by qPCR or dPCR.
In an attempt to exclude the potential negative role of BRAF
mutations, we evaluated the predictive value of low-frequent
RAS-mutant alleles in the RAS/BRAF wild-type population
assessed by qPCR. Results were similar to those observed in
the RAS wild-type population, since the higher sensitive cut-
off did not improve the predictability to treatment response
(supplementary Table S4, available at Annals of Oncology
online).
At database lock (July 2016), the median follow-up was 12.3
(0.7–34.2) months. Patients showed a median PFS of 7.1 months
(95% CI, 5.8–8.5) and OS of 13.7 months (95% CI, 9.4–18).
Survival outcome analyses according to RAS and RAS/BRAF sta-
tus by qPCR and dPCR cut-offs in the RAS wild-type population
are described in Table 4. When using dPCR, the 5% cut-off
showed the highest PFS in wild-type patients with the lowest PFS
in those with mutated RAS (7.6 versus 4.0 months, P-value ¼
0.048) and RAS/BRAF (8.8 versus 4.0 months, P-value < 0.001).
These figures were similar to those observed when using qPCR,
with the exception of a slightly higher PFS in wild-type RAS/
BRAF patients by dPCR compared to qPCR (8.8 versus
7.6 months). We also evaluated survival in the RAS/BRAF wild-
type population by qPCR according to different RAS mutant al-
lele fractions. We observed that the presence of RAS mutations at
frequency below 5% did not improve survival outcomes, since
PFS was similar in RAS wild-type and mutant patients (supple-
mentary Table S5, available at Annals of Oncology online).
Discussion
The identification of predictive biomarkers to EGFR inhibitors to
select patients more likely to benefit from these therapies is still a
matter of concern. The expanded mutational analysis to KRAS
and NRAS exon 2, 3 and 4 has been widely explored in retrospect-
ive and prospective studies associated to clinical trials and its as-
sessment is mandatory before anti-EGFR therapies, whereas
there is still insufficient data for BRAF [6, 7], although it is highly
recommended by international guidelines [14]. The role of add-
itional low-abundant mutations in the EGFR pathway genes ra-
ther than RAS exon 2, 3 and 4 mutations has been addressed
previously in retrospective studies suggesting that the optimal
cut-off for patient selection is >1% [12, 13, 15, 16]. However,
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there is a need for further validation. In this sense, we report the
results of the first published clinical trial addressing this question.
Nanofluidic dPCR allowed the identification of higher rates
of gene mutations, most of them located in KRAS exons 2/3. It
is remarkable that additional low-abundant mutations in
KRAS exon 4, NRAS and/or PIK3CA were detected in more
than 20% of patients, similar to data published previously [12,
13, 15, 16].
Table 1. Baseline patient characteristics (overall population and patients with RAS wild-type population by qPCR)
Characteristics Value Value
Overall population RAS wild-type by qPCR
N 5 72 N 5 65
Median age, years (range) 62 (38–83) 62 (38–83)
Gender, n (%)
Male 51 (71) 46 (71)
Female 21 (29) 19 (29)
Tumour stage at initial diagnosis, n (%)
II 4 (5.6) 4 (6.2)
III 16 (22.2) 14 (21.5)
IV 52 (72.2) 47 (72.3)
Karnofsky performance status, n (%)
70–80 18 (25) 14 (21.5)
90–100 54 (75) 51 (78.5)
Primary tumour site, n (%)
Right colon 10 (14) 9 (13.8)
Left colon 31 (43) 31 (47.7)
Rectum 31 (43) 25 (38.5)
Primary tumour surgery, n (%)
Yes 53 (74) 49 (75.4)
No 19 (26) 16 (24.6)
Number of metastatic sites, n (%)
<3 49 (68) 45 (69.2)
3 23 (32) 20 (30.8)
Adjuvant chemotherapy (non-metastatic disease)
Flouropyrimidine monotherapy 4 (5.6) 4 (6.1)
Flouropyrimidine þ oxaliplatin 12 (16.7) 11 (17)
Observation 4 (5.6) 3 (4.6)
Previous therapies for metastatic disease
Neoadjuvant/adjuvant
Oxaliplatin-based chemotherapy 6 (8.3) 5 (7.7)
Irinotecan-based chemotherapy 1 (1.4) 0 (0)
Folfoxiri-based chemotherapy 1 (1.4) 1 (1.5)
First line
Oxaliplatin-based chemotherapy 30 (41.7) 25 (38.5)
Irinotecan-based chemotherapy 38 (52.7) 36 (55.4)
Folfoxiri-based chemotherapy 4 (5.6) 4 (6.2)
Second line
Oxaliplatin-based chemotherapy 7 (9.7) 6 (9.2)
Irinotecan-based chemotherapy 27 (37.5) 23 (35.4)
Flouropyrimidine monotherapy 2 (2.8) 2 (3.1)
Third line
Irinotecan-based chemotherapy 4 (5.6) 4 (6.2)
Oxaliplatin-based chemotherapy 1 (1.4) 1 (1.5)
Fourth line and beyond
Irinotecan-based chemotherapy 3 (4.2) 2 (3.1)
Others 1 (1.4) 1 (1.5)
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In terms of efficacy, we have shown that BRAF mutations
are clearly associated with poor outcome, independently of the
technique used, as reported previously from randomized clinical
trials [5, 17]. Additionally, extended mutational RAS (KRAS/
NRAS) and RAS/BRAF status translated into differential clinical
outcomes defined by dPCR sensitivity cut-offs.
This is in line with the more evident benefit of anti-EGFR
therapies in patients with wild-type RAS/BRAF tumours observed
in retrospective extended analyses of tumour tissues from case
series and clinical trials using dPCR [12, 13]. However, identify-
ing optimal fractions of mutated alleles that predict anti-EGFR-
therapy outcomes remain challenging. In this phase II clinical
Table 2. Mutation distribution (N5 72)
Conventional qPCR, n (%) Nanofluidic dPCR, n (%)
Wild-type Mutation Wild-type Mutation
KRAS 67 (93) 5 (7) 52 (72) 20 (28)
Exon 2-codon 12–13 71 (99) 1 (1) 62 (86) 10 (14)a
Exon 3-codon 58–61 70 (97) 2 (3) 65 (90) 7 (10)a
Exon 4-codon 117 72 (100) 0 (0) 71 (99) 1 (1)
Exon 4-codon 146 70 (97) 2 (3) 69 (96) 3 (4)
NRAS 70 (97) 2 (3) 67 (93) 5 (7)
Exon 2-codon 12–13 71 (99) 1 (1) 69 (96) 3 (4)a,b
Exon 3-codon 59–61 71 (99) 1 (1) 69 (96) 3 (4)a,b
Exon 4-codon 117 72 (100) 0 (0) 72 (100) 0 (0)
Exon 4-codon 146 72 (100) 0 (0) 71 (99) 1 (1)
BRAF 68 (94) 4 (6) 68 (94) 4 (6)
Exon 15-codon 600 68 (94) 4 (6) 68 (94) 4 (6)
PIK3CA 71 (99) 1 (1) 70 (97) 2 (3)
Exon 20-codon 1043–1047 71 (99) 1 (1) 70 (97) 2 (3)
dPCR, digital PCR; qPCR, quantitative PCR.
aOne patient exhibited two mutations: one in codon 12 and another in codon 59.
bOne patient exhibited two mutations: one in codon 12 and another in codon 61.
Better mutation Better wild type│







Odds Ratio and rate for Overall Response RAS (KRAS+NRAS ) wt vs mutation +/- 95%CI





OR = 1.2  (49 vs 44)
OR = 1.5  (50 vs 40)
OR = 2  (50 vs 33)
OR = 2.5  (50 vs 29)
OR = 1.4  (48 vs 40)
OR = 1.4  (48 vs 40)
OR = 1.9  (48 vs 33)
Better mutation Better wild type│







Odds Ratio and rate for Overall Response RAS+BRAF wt vs mutation +/- 95%CI





OR = 1.6  (51 vs 39)
OR = 2  (52 vs 35)
OR = 3.4  (53 vs 25)
OR = 4.5  (53 vs 20)
OR= 3.8  (52 vs 22)
OR = 3.8  (52 vs 22)
OR = 6.4  (52 vs 14)
Figure 1. Overall response rates in wild-type versus RAS and RAS/BRAF mutations detected by nanofluidic digital PCR (N¼ 65). Odds ratios
and their 95% confidence intervals are represented, along with the description of overall response rates for each cut-off value. CI, confidence
interval; OR, odds ratio; vs, versus; wt, wild-type.
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trial, sensitivity of RAS/BRAF mutational analysis of dPCR cut-
offs for clinical outcome prediction was 5%, as the presence of
mutations <5% was not associated with inferior response rate
or survival. We have to point out that it was not possible to
evaluate the predictive/prognostic value of BRAF minor sub-
clones since BRAF-mutant allele fraction was>10% in all cases.
Increasing analytical sensitivity using dPCR may entail draw-
backs in terms of patient selection, as clinical outcomes
observed in patients with RAS and BRAF mutations were higher
when using lower cut-offs. This effect was less evident and com-
parable to conventional qPCR when a 5% dPCR cut-off was
used. However, previous retrospective analyses have reported
even lower optimal thresholds when using nanofluidic dPCR
[12, 13].
Other types of high-sensitive dPCR have also faced the chal-
lenging scenario of assessing the most appropriate threshold to
identify patients most likely to benefit from anti-EGFR thera-
pies [15, 16]. While an analysis of the clinical relevance of
KRAS-mutated subclones assessed by picodroplet dPCR
reported a 1% threshold in mCRC patients treated with cetuxi-
mab or panitumumab [15], another outcome analysis using
BEAMING dPCR showed that mCRC patients with RAS muta-
tion signals from 0.1% to 5% may benefit from adding cetuxi-
mab to FOLFIRI [16]. Despite the current evidence suggests
different optimal cut-offs for outcome prediction, it is note-
worthy that a minimum of mutant alleles is required to confer
primary resistance to anti-EGFR drugs. Several hypotheses be-
yond those related to the retrospective nature of the studies, the
heterogeneity of patient populations and analytical methods
could explain the slight discrepancies among publications.
Intratumour heterogeneity has been recently described as a
mechanism likely to affect the response to anti-EGFR [18, 19],
pointing out the potential cooperative effect of EGFR pathway
genes mutations on outcome, even though these mutations
were present in a low frequency. The clonal selection under
treatment pressure has also been involved in the treatment effi-
cacy to target agents such as anti-EGFR [20–22]. Moreover,
additional factors such as tumour site (right versus left colon)
and other molecular alterations could be responsible for intrin-
sic resistance [9, 23–26].
The authors acknowledge certain study limitations that
should be considered when interpreting its findings, including
the impossibility to assess the role of PIK3CA status due to the
low number of mutations. In addition, initially enrolled
patients may have had mutations in KRAS 3/4 exons and NRAS
2/3/4 exons, while patients must have had no mutation in KRAS
and NRAS exons 2/3/4 after the approval of protocol amend-
ment on 25 July 2013. The analysis of KRAS/RAS status to assess
patient eligibility could have been performed either by the local
laboratory conventional technique or by conventional qPCR in
the central laboratory. Nonetheless, tumour tissues from
enrolled patients were analysed by conventional qPCR in the
central laboratory to ensure homogeneity in study results. As
expected, 10% of tumour samples harboured mutations in
KRAS exon 3 or 4 or in NRAS exon 2, 3 or 4 by standard of care,
which translated into a RAS wild-type population of 65
patients.
In conclusion, although the predictive role of PIK3CA status
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optimal RAS/BRAF mutational cut-off for outcome prediction is
5% within the range of analytical sensitivity of conventional
methods, which explains that the predictive performance
of qPCR was not improved by dPCR in our study. Further re-
search on the biological role and clinical relevance of low-fre-
quent mutations (1%–5%) is warranted. Larger datasets may be
important to re-assess the effect of ultra-selection, since minimal
but significant effect would need greater numbers to be proven.
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Table 4. Survival according to mutational status in the RAS wild-type population (N 5 65)
Conventional qPCR Nanofluidic dPCR
Cut-off 0% Cut-off 0.1% Cut-off 1% Cut-off 2% Cut-off 3% Cut-off 4% Cut-off 5%
RAS (KRAS/NRAS)
PFS, months
wt/mut (n/n) 65/– 49/16 50/15 56/9 58/7 60/5 60/5 62/3
Median (wt/mut) 7.4/– 7.2/7.4 7.6/7.4 7.6/7.4 7.6/6.7 7.6/7.4 7.6/7.4 7.6/4.0
HR (95% CI) – 0.9 (0.5–1.6) 0.9 (0.5–1.7) 0.8 (0.4–1.8) 1.3 (0.6–2.9) 1.0 (0.4–2.5) 1.0 (0.4–2.5) 3.3 (1.0–11.0)
P-value – 0.741 0.818 0.657 0.513 0.996 0.996 0.048
OS, months
wt/mut (n/n) 65/– 49/16 50/15 56/9 58/7 60/5 60/5 62/3
Median (wt/mut) 13.9/– 11.7/17.4 11.8/16.1 12.5/16.1 13.9/16.1 13.9/16.1 13.9/16.1 13.9/16.1
HR (95% CI) – 0.6 (0.3–1.2) 0.7 (0.3–1.4) 0.6 (0.3–1.7) 0.8 (0.3–2.1) 0.8 (0.3–2.2) 0.8 (0.3–2.2) 1.5 (0.4–4.7)
P-value – 0.142 0.294 0.367 0.689 0.620 0.620 0.534
RAS/BRAF
PFS, months
wt/mut (n/n) 61/4 47/18 48/17 53/12 55/10 56/9 56/9 58/7
Median (wt/mut) 7.6/1.8 7.6/6.7 7.6/6.7 7.6/5.5 8.1/4.6 8.1/4.6 8.1/4.6 8.8/4.0
HR (95% CI) 6.0 (2.0–17.7) 1.0 (0.6–1.8) 1.0 (0.6–1.9) 1.1 (0.6–2.2) 1.7 (0.9–3.4) 1.7 (0.8–3.4) 1.7 (0.8–3.4) 5 (2.1–11.7)
P-value 0.001 0.965 0.879 0.732 0.123 0.160 0.160 <0.001
OS, months
wt/mut (n/n) 61/4 47/18 48/17 53/12 55/10 56/9 56/9 58/7
Median (wt/mut) 16.1/6.2 11.8/16.1 12.5/16.1 13.9/13.7 15.6/8.4 16.2/8.4 16.2/8.4 16.2/7.3
HR (95% CI) 8.1 (2.6–25.5) 0.7 (0.4–1.4) 0.8 (0.4–1.7) 1.0 (0.5–2.2) 1.3 (0.6–2.8) 1.5 (0.7–3.3) 1.5 (0.7–3.3) 2.8 (1.3–6.4)
P-value <0.001 0.349 0.619 0.951 0.528 0.290 0.290 0.012
CI, confidence interval; dPCR, digital PCR; HR, hazard ratio; mut, mutation; OS, overall survival; PFS, progression-free survival; qPCR, quantitative PCR; wt,
wild-type.
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